We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dihydromyricetin promotes hepatocellular carcinoma regression via a p53 activation-dependent mechanism.
- Authors
Qingyu Zhang; Jie Liu; Bin Liu; Juan Xia; Nianping Chen; Xiaofeng Chen; Yi Cao; Chen Zhang; CaiJie Lu; Mingyi Li; Runzhi Zhu
- Abstract
The development of antitumor chemotherapy drugs remains a key goal for oncologists, and natural products provide a vast resource for anti-cancer drug discovery. In the current study, we found that the flavonoid dihydromyricetin (DHM) exhibited antitumor activity against liver cancer cells, including primary cells obtained from hepatocellular carcinoma (HCC) patients. In contrast, DHM was not cytotoxic to immortalized normal liver cells. Furthermore, DHM treatment resulted in the growth inhibition and remission of xenotransplanted tumors in nude mice. Our results further demonstrated that this antitumor activity was caused by the activation of the p53-dependent apoptosis pathway via p53 phosphorylation at serine (15Ser). Moreover, our results showed that DHM plays a dual role in the induction of cell death when administered in combination with cisplatin, a common clinical drug that kills primary hepatoma cells but not normal liver cells.
- Subjects
LIVER cancer; ONCOLOGISTS; CANCER chemotherapy; DRUG therapy; HEPATOCELLULAR carcinoma; CISPLATIN; LIVER tumors
- Publication
Scientific Reports, 2014, p1
- ISSN
2045-2322
- Publication type
Article
- DOI
10.1038/srep04628